Safety of Megadosage Haloprogin

Walter T. Hughes; Sandor Feldman; Harold W. Hermann

doi:10.1001/archderm.1974.01630120072018

Safety of Megadosage Haloprogin

Walter T. Hughes, Sandor Feldman, Harold W. Hermann

School of Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

A 4-year-old girl with unremitting chronic mucocutaneous candidiasis since 9 months of age was treated topically with haloprogin for a total of 460 days in seven periods of consecutive weeks to months over a 3-year span. During that time, she was given 403 tubes or bottles (30 gm or ml) amounting to about 12,090 gm of a product containing 1% haloprogin. Biochemical, hematologic, and urine examinations were used in monitoring the patient's condition during treatment and showed no evidence of systemic or dermal toxicity.

Original language	English (US)
Pages (from-to)	926-928
Number of pages	3
Journal	Archives of Dermatology
Volume	110
Issue number	6
DOIs	https://doi.org/10.1001/archderm.1974.01630120072018
State	Published - Dec 1974

ASJC Scopus subject areas

Dermatology

Access to Document

10.1001/archderm.1974.01630120072018

Cite this

@article{ae0fe9863e7e4a53a7cd6d9e550dc996,

title = "Safety of Megadosage Haloprogin",

abstract = "A 4-year-old girl with unremitting chronic mucocutaneous candidiasis since 9 months of age was treated topically with haloprogin for a total of 460 days in seven periods of consecutive weeks to months over a 3-year span. During that time, she was given 403 tubes or bottles (30 gm or ml) amounting to about 12,090 gm of a product containing 1% haloprogin. Biochemical, hematologic, and urine examinations were used in monitoring the patient's condition during treatment and showed no evidence of systemic or dermal toxicity.",

author = "Hughes, {Walter T.} and Sandor Feldman and Hermann, {Harold W.}",

year = "1974",

month = dec,

doi = "10.1001/archderm.1974.01630120072018",

language = "English (US)",

volume = "110",

pages = "926--928",

journal = "Archives of Dermatology",

issn = "0003-987X",

publisher = "American Medical Association",

number = "6",

}

TY - JOUR

T1 - Safety of Megadosage Haloprogin

AU - Hughes, Walter T.

AU - Feldman, Sandor

AU - Hermann, Harold W.

PY - 1974/12

Y1 - 1974/12

N2 - A 4-year-old girl with unremitting chronic mucocutaneous candidiasis since 9 months of age was treated topically with haloprogin for a total of 460 days in seven periods of consecutive weeks to months over a 3-year span. During that time, she was given 403 tubes or bottles (30 gm or ml) amounting to about 12,090 gm of a product containing 1% haloprogin. Biochemical, hematologic, and urine examinations were used in monitoring the patient's condition during treatment and showed no evidence of systemic or dermal toxicity.

AB - A 4-year-old girl with unremitting chronic mucocutaneous candidiasis since 9 months of age was treated topically with haloprogin for a total of 460 days in seven periods of consecutive weeks to months over a 3-year span. During that time, she was given 403 tubes or bottles (30 gm or ml) amounting to about 12,090 gm of a product containing 1% haloprogin. Biochemical, hematologic, and urine examinations were used in monitoring the patient's condition during treatment and showed no evidence of systemic or dermal toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0016380986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016380986&partnerID=8YFLogxK

U2 - 10.1001/archderm.1974.01630120072018

DO - 10.1001/archderm.1974.01630120072018

M3 - Article

C2 - 4479934

AN - SCOPUS:0016380986

SN - 0003-987X

VL - 110

SP - 926

EP - 928

JO - Archives of Dermatology

JF - Archives of Dermatology

IS - 6

ER -

Safety of Megadosage Haloprogin

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this